The use of the ADCC competent monoclonal antibody, rituximab, in combination with the fusion protein L19-IL2 has also been shown to enhance activity compared to rituximab alone in B-cell lymphoma models55. This evidence concerns the gene IL2 and B-cell non-Hodgkin lymphoma.